Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.
bioscience. questions. answered.

In US and Canada Call Toll Free: (877) 597-9236
Everywhere Else Call: (760) 431-6300

Reports

2009 Transfection Dashboard Series 2 -

reportimageCatalog number: 0910TFN
Publication date: October 2009
Company-wide electronic copy: Complimentary

Please inquire about single-user* electronic copy pricing
* single-user pricing is intended for small companies, of 40 or less employees, to access The Life Science Dashboard. Please order these copies directly with Percepta Associates.

Overview

Introduction

The ability to transfect DNA into mammalian cells and cell lines is a critical step in the analysis of gene expression, protein structure and function and molecular interactions within the cell. The Transfection Dashboard Series Two was developed from responses to a 24-question survey completed by over 427 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the transfection market as a whole as well as for the following sub-segments:

  • Chemically-mediated transfection (i.e. calcium phosphate)
  • Lipid-mediated transfection
  • Instrument-mediated transfection (i.e. electroporator, Nucleofector®)
  • Virus-mediated transfection (Note: for the purposes of this report, virus-mediated transfection refers to the delivery of nucleic acid material into mammalian cells or cell lines using virus and/or viral-based gene delivery systems).

The genomics revolution has set the table for the study of gene expression & regulation as well as protein structure and function. The technique of transfection is a necessary precursor to many of the methods we rely on to build upon the knowledge gained by genome sequencing projects, including:

  • Gene silencing studies
  • in vivo analysis of protein expression
  • Reporter gene assays

In order to dive more deeply into the characteristics and dynamics of the market for transfection products, Percepta has launched the Series 2 Transfection Dashboard 2009, designed to take a snapshot of the current market landscape.

Survey Methodology

In August of 2009, Percepta fielded the Mammalian Transfection Survey to a subset of the Percepta BioAnalytix™ Panel of life scientists. Individuals were invited by e-mail blast to click through to a webpage at bioanalytix.com where the survey was hosted.

Invitations were delivered on August 1, 2009 and results collected through August 10. A total of 427 scientists completed the survey, of which 375 are actively engaged in the transfection of mammalian cells or cell lines.

Results based on the aggregate of collected responses are revealed in this Transfection Dashboard.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented. 66.3% of respondents work at universities/colleges/medical schools; 9.0% are employed at hospitals/medical centers; 10.1% of respondents work for biotechnology companies; 4.1% are employed by pharmaceutical companies. Overall, 15.0% of respondents work in industrial laboratories.

About 85% of respondents are from North America, with most of the remaining 15% residing in Europe.

Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior-level (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Professor/Principal Investigator (19.3%), Scientist/Senior Scientist (17.5% of respondents) and Post-Doctoral Fellow (15.8%).

A wide variety of scientific areas of specialization is also evident, led by molecular biology (indicated by 30.3% of respondents as their primary area of expertise), cell biology (16.2%) and biochemistry (9.3%).

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented. A total of 60.7% of survey participants work in labs where between 1 and 5 people perform transfection experiments; 15.2% are employed in labs where 6 to 10 people perform the method. 4.6% of respondents are employed in labs where between 11 and 20 people perform transfection experiments, while the remaining 19.5% of respondents work in labs where greater than twenty people perform the method.

Table of contents

Table of Contents

  • 6 Figures and Tables
  • 10 Executive Summary
  • 12 Key Findings and Implications
  • 15 Transfection Dashboard
  • 19 Transfection Market Opportunity Matrix
  • 21 Survey Methodology
  • 22 Survey Invitation Text
  • 24 Respondent Demographics
  • 37 Frequency of Performance of Life Science Techniques
  • 42 Frequency of Transfection of Mammalian Cells or Cell Lines
  • 54 Reaction Throughput and Market Growth Rates
  • 60 Respondent’s Stated Price Per Reaction
  • 63 Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • 66 Market Shares for Products for Chemically-Mediated Transfection of Mammalian Cells or Cell Lines
  • 70 Market Shares for Products for Lipid-Mediated Transfection of Mammalian Cells or Cell Lines
  • 74 Market Shares for Products for Instrument-Mediated Transfection of Mammalian Cells or Cell Lines
  • 78 Market Shares for Products for Virus-Mediated Transfection of Mammalian Cells or Cell Lines
  • 83 Customer Satisfaction And Interest In Switching Suppliers
  • 90 Product Features That Influence Purchasing Decisions
  • 94 Primary and Secondary Downstream Applications
  • 114 Desired Changes to Transfection Products
  • 122 Survey Questionnaire

Figures and Tables

  • 26 Figure 1: Respondent’s Place of Employment
  • 28 Figure 2: Respondent’s Country/Region
  • 30 Figure 3: Respondent’s Job Title
  • 32 Figure 4: Respondent’s Areas of Expertise/Specialization
  • 36 Figure 5: Number of Employees in Respondent’s Laboratories
  • 39 Figure 6: Percentage of Respondents Performing Various Life Science Techniques at Least a Few Times per Year
  • 44 Figure 7: Percentage of Respondents Transfecting Mammalian Cells or Cell Lines
  • 44 Figure 8: Percentage of Respondents Performing Transfection of Mammalian Cells or Cell Lines at Least a Few Times Per Year
  • 47 Figure 9: Percentage of Respondents Performing Chemically-Mediated Transfection of Mammalian Cells or Cell Lines
  • 48 Figure 10: Percentage of Respondents Performing Lipid-Mediated Transfection of Mammalian Cells or Cell Lines
  • 49 Figure 11: Percentage of Respondents Performing Instrument-Mediated Transfection of Mammalian Cells or Cell Lines
  • 50 Figure 12: Percentage of Respondents Performing Virus-Mediated Transfection of Mammalian Cells or Cell Lines
  • 67 Figure 13: Respondent’s Primary Supplier for Chemically-Mediated Transfection of Mammalian Cells or Cell Lines
  • 71 Figure 14: Respondent’s Primary Supplier for Lipid-Mediated Transfection of Mammalian Cells or Cell Lines
  • 75 Figure 15: Respondent’s Primary Supplier for Instrument-Mediated Transfection of Mammalian Cells or Cell Lines
  • 79 Figure 16: Respondent’s Primary Supplier for Virus-Mediated Transfection of Mammalian Cells or Cell Lines
  • 88 Figure 17: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • 89 Figure 18: Percentage of Respondents That Have Switched from the following Suppliers to a Different Supplier in the Last Six Months
  • 92 Figure 19: Most Important Features of Transfection Products
  • 96 Figure 20: Respondent’s Primary Application for Mammalian Cells or Cell Lines After Chemically-Mediated Transfection
  • 98 Figure 21: Respondent’s Primary and Secondary Applications for Mammalian Cells or Cell Lines After Chemically-Mediated Transfection
  • 101 Figure 22: Respondent’s Primary Application for Mammalian Cells or Cell Lines After Lipid-Mediated Transfection
  • 103 Figure 23: Respondent’s Primary and Secondary Applications for
    Mammalian Cells or Cell Lines After Lipid-Mediated Transfection
  • 106 Figure 24: Respondent’s Primary Applications for Mammalian Cells or Cell Lines After Instrument-Mediated Transfection
  • 108 Figure 25: Respondent’s Primary and Secondary Applications for Mammalian Cells or Cell Lines After Instrument-Mediated Transfection
  • 111 Figure 26: Respondent’s Primary Applications for Mammalian Cells or Cell Lines After Virus-Mediated Transfection
  • 113 Figure 27: Respondent’s Primary and Secondary Applications for Mammalian Cells or Cell Lines After Instrument-Mediated Transfection

Questionnaire

Available upon request

Copyright © 2017 Percepta Associates Inc. All rights reserved. Terms & Conditions.Designed by Audacity